@article {D{\textquoteright}ONOFRIO1305, author = {MIRKO D{\textquoteright}ONOFRIO and SARA CINGARLINI and SILVIA ORTOLANI and STEFANO CROSARA and RICCARDO DE ROBERTIS and PAOLA VALLERIO and ELISABETTA GREGO and VALENTINA CIARAVINO and ANDREA RUZZENENTE and LUCA LANDONI and ALDO SCARPA and CLAUDIO BASSI and GIAMPAOLO TORTORA}, title = {Perfusion CT Changes in Liver Metastases from Pancreatic Neuroendocrine Tumors During Everolimus Treatment}, volume = {37}, number = {3}, pages = {1305--1311}, year = {2017}, publisher = {International Institute of Anticancer Research}, abstract = {Aim: To evaluate modifications of perfusional parameters assessed by perfusion computed tomography (P-CT) of liver metastases (LM) from pancreatic neuroendocrine tumors (PanNETs) during everolimus treatment. Patients and Methods: All patients with LMs from G1-2 PanNETs undergoing everolimus treatment between January 2013 and January 2015 were prospectively evaluated with P-CT at baseline, and after 2 and 4 months of therapy. Size, perfusion, blood volume (BV), peak enhancement intensity (PEI) and time to peak for each lesion were calculated. Results: A total of 33 LMs in nine patients with G1-2 PanNETs were prospectively evaluated: 23/33 (69.7\%) were responders, 10/33 (30.3\%) were non-responders. Among perfusional parameters, only numerical peak enhancement intensity values significantly differed between the two groups at baseline (p=0.043). BV increase was the most significant perfusional modification identifying responding lesions, even at an early stage of treatment, with a high positive predictive value (89.47\%). Conclusion: P-CT seems to be useful for prediction of response to everolimus of LMs from PanNETs.}, issn = {0250-7005}, URL = {https://ar.iiarjournals.org/content/37/3/1305}, eprint = {https://ar.iiarjournals.org/content/37/3/1305.full.pdf}, journal = {Anticancer Research} }